Papa's Exit Highlights Perrigo's Shortcomings

After Papa's exit from Perrigo, the company is left to pick up the pieces and is not as strong a business as investors had previously thought.

With Perrigo Co. PLC's CEO moving on to murkier waters, questions have arisen about the health of the company's own business. While some worry that the company will change course, a change might be exactly what Perrigo needs to get back to former highs.

The maker of generic and over-the-counter drugs has seen a slip of 55% in its stock price from its 52-week...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.